U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco ...
Active ingredient: Ciclesonide 80 µg/inhalation, 160 µg/inhalation; metered-dose inhaler. Indication: Maintenance treatment of asthma as prophylactic therapy in patients >12 years of age. Pharmacology ...
September 18, 2006 — Health Canada has approved inhaled ciclesonide for the prophylaxis of steroid-responsive bronchial asthma in patients aged 18 years or older; the European Commission has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback